Fosamax® Femur Fractures Lawyer & Lawsuit

Tweet

A new study confirms that long-term use of bisphosphonates like Fosamax increases the risk for atypical (subtrochanteric or femoral shaft) fractures in older women. Use of these drugs has been found to suppress bone remodeling, leading to unusual fractures. Patients advised to weigh risks vs. benefits closely before taking Fosamax.

Fosamax Lawsuit Update 5/15/12: A federal judge has barred pharmaceutical giant Merck & Co. from contacting the doctors of patients who have filed Fosamax bone fracture lawsuits. Citing physician-client privilege, Judge Joel A. Pisano stated that it would be inappropriate for the company to directly contact plaintiff physicians in any way outside the presence of their attorneys. Click here to learn more.

Fosamax Bone Fracture Update 5/11/12: Researchers from the U.S. Food & Drug Administration (FDA) are expressing concern over the risk of bone fractures associated with the long-term use of a number of popular osteoporosis drugs from the bisphosphonate class. In an article published this week in the New England Journal of Medicine (NEJM), FDA researchers stated they were still uncertain as to the optimal duration for use of bisphosphonates, due to the high number of reports of atypical bone fractures in users of the drugs. Click here to learn more.

Free Fosamax Femur Fracture Case Evaluation: If you or a loved one has been injured by Fosamax, you should contact our law firm immediately. You may be entitled to compensation by filing a lawsuit and we can help.

What’s the problem?

February 23, 2011 - Breaking News: A study published today in the Journal of the American Medical Association reports that the long-term use of bisphosphonates such as Actonel, Aredia, Boniva, Fosamax, and Zometa increases the risk for atypical (subtrochanteric or femoral shaft) fractures in older women.

The crux of the study evaluated the link between hospitalization for a subtrochanteric or femoral shaft fracture and the duration of bisphosphonate therapy. After starting bisphosphonate therapy, 716 women had a subtrochanteric or femoral shaft fracture, and 9,723 women had a typical osteoporotic fracture of the intertrochanteric region or femoral neck. The study found that the risk for these fractures was increased among women treated with bisphosphonates for at least 5 years vs those who had only transient use.

Among women taking bisphosphonates for longer than 5 years, more than half of subtrochanteric or femoral shaft fractures could be attributed to extended bisphosphonate use. Additional analysis suggested that if no patient received more than 5 years of bisphosphonate exposure, approximately 1 of every 10 cases of subtrochanteric or femoral shaft fractures in the population might be prevented.

“These findings also highlight the need for a thoughtful assessment of individual risk of fracture when considering extended bisphosphonate therapy and that long-term use of these drugs may warrant reconsideration, especially in patients at relatively low risk of fracture,” the study authors conclude.

In October 2010, the U.S. Food & Drug Administration (FDA) required bisphosphonate labels to include a warning regarding an increased risk for subtrochanteric or femoral shaft fractures.

Do I have a Fosamax Femur Fracture Lawsuit?

The Product Liability & Defective Drug Litigation Group at our law firm is an experienced team of trial lawyers that focus on the representation of plaintiffs in Fosamax lawsuits. We are handling individual litigation nationwide and currently accepting new femur fracture cases in all 50 states.